287 related articles for article (PubMed ID: 23885909)
1. Personalized oncology in interventional radiology.
Abi-Jaoudeh N; Duffy AG; Greten TF; Kohn EC; Clark TW; Wood BJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1083-92; quiz 1093. PubMed ID: 23885909
[TBL] [Abstract][Full Text] [Related]
2. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.
Marshall D; Laberge JM; Firetag B; Miller T; Kerlan RK
J Vasc Interv Radiol; 2013 Aug; 24(8):1094-103. PubMed ID: 23806383
[TBL] [Abstract][Full Text] [Related]
3. Personalized therapy for non-small cell lung cancer: which drug for which patient?
Villaruz LC; Socinski MA
Semin Thorac Cardiovasc Surg; 2011; 23(4):281-90. PubMed ID: 22443647
[TBL] [Abstract][Full Text] [Related]
4. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
6. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
7. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L; Fu L
Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
10. Companion biomarkers: paving the pathway to personalized treatment for cancer.
Duffy MJ; Crown J
Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
[TBL] [Abstract][Full Text] [Related]
11. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
12. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
15. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
16. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
18. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
19. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
[Next] [New Search]